WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.


L04 IMMUNOSUPPRESSANTS

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.


L04A IMMUNOSUPPRESSANTS

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.


L04AA Selective immunosuppressants

Antilymphocyte immunoglobulin from horse serum is classified in L04AA03.
Antithymocyte immunoglobulin from rabbit serum is classified in L04AA04.
Oral formulations of cladribine used in multiple sclerosis are classified in this group, while parenteral formulations for cancer are classified in L01BB.

The DDD for abatacept is based on the treatment of rheumatoid arthritis.
The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.


    ATC code  Name  DDD  U Adm.R Note
    L04AA06 mycophenolic acid as mycophenolate mofetil
    as mycophenolate mofetil

List of abbreviations

Last updated: 2024-01-26